Aytu BioPharma vs Journey Medical
AYTU and DERM side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AYTU and DERM compare
Journey Medical is the larger company, worth 6.4 times as much as Aytu BioPharma ($124M against $19.5M).
Journey Medical grew revenue faster over the last twelve months (17.0% versus −13.3% for Aytu BioPharma).
Journey Medical keeps more of each dollar of sales as profit, with a net margin of −7.3% compared with −24.8% at Aytu BioPharma.
Aytu BioPharma scores higher on the StockData Score (9 against 7 for Journey Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AYTU | DERM |
|---|---|---|
| Size and price | ||
| Market cap | $19.5M | $124M |
| Share price | $1.79 | $4.39 |
| Change, 1 year | −14.8% | −51.5% |
| Change, 5 years | −95.6% | −50.1% |
| Beta (5Y) | 1.05 | 0.68 |
| Employees | 76 | 58 |
| StockData Score | ||
| Total score | 9 (better) | 7 |
| Valuation score | 3 (better) | 2 |
| Growth score | 0 | 1 (better) |
| Performance score | 3 | 3 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 1.8× |
| P/B | 0.6× (better) | 3.8× |
| P/FCF | 6.0× | – |
| FCF yield | 16.7% | – |
| Fair value | $8.68 | $5.78 |
| Margin of safety | 79.4% (better) | 24.0% |
| Growth | ||
| Revenue growth (TTM) | −13.3% | 17.0% (better) |
| Revenue growth, 5Y average | −2.6% | 6.8% (better) |
| Profitability | ||
| Gross margin | 64.0% | 65.9% (better) |
| Operating margin | −14.4% | −2.9% (better) |
| Net margin | −24.8% | −7.3% (better) |
| FCF margin | 5.6% | – |
| Return on equity | −52.6% | −17.6% (better) |
| Return on invested capital | −63.5% | −5.2% (better) |
| Financial health | ||
| Debt / equity | 0.31 (better) | 0.79 |
| Interest coverage | −4.4× | −0.6× (better) |
| Current ratio | 1.13 | 1.48 (better) |
| Altman Z-score | −4.10 | 0.56 (better) |
| Piotroski F-score | 3 | 5 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 45.3% | 37.8% |
| Held by insiders | 15.1% | 15.3% |
| Short interest, % of float | 3.3% | 12.9% |
Go deeper
- AYTU stock overview
- AYTU income statement
- AYTU valuation and score
- DERM stock overview
- DERM income statement
- DERM valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.